In an alopecia areata trial, a novel bifunctional therapy that blocks signaling of the interleukin-7 and TSLP pathways ...

A YOUNG woman who developed stress-related alopecia has revealed how she went from being almost bald to having a bob in less ...

ORLANDO -- More than 80% of patients with moderate or severe atopic dermatitis (AD) had at least 75% improvement after 12 ...

The BRAVE-AA-PEDS trial found that once-daily baricitinib significantly improved hair regrowth on the scalp, eyebrows, and ...

For adults with severe alopecia areata (AA), ivarmacitinib, a selective Janus kinase 1 (JAK1) inhibitor, at doses of 4 and 8 ...

Bempikibart demonstrated positive, durable responses among patients with severe to very severe alopecia areata, according to ...

Thirty-six weeks of once-daily, oral baricitinib was associated with greater hair regrowth on the scalp, eyebrows and ...

A research group, led by Dr. Pavel Majer from IOCB Prague, in collaboration with the laboratories of Barbara Slusher and ...

For adults with severe alopecia areata (AA), ivarmacitinib, a selective Janus kinase 1 (JAK1) inhibitor, at doses o ...

In an interview with Brittany Craiglow, MD, FAAD, dermatologist at Dermatology Physicians of Connecticut in Fairfield, she advocates for combination therapies using baricitinib to treat pediatric ...

Eli Lilly (NYSE:LLY) has recently unveiled significant advancements across its product line, including promising results from ...

Eli Lilly and INCY announce positive efficacy data from the late-stage alopecia study of baricitinib in adolescent patients.